BIC/FTC/TAF for HIV Post-Exposure Prophylaxis
Recommended Dosing Regimen
- The CDC recommends BIC/FTC/TAF as a preferred regimen for adults and adolescents requiring PEP, administered as a single tablet once daily for 28 days for complete HIV post-exposure prophylaxis 1, 2, 4
- BIC/FTC/TAF is available as a fixed-dose combination (FDC) tablet, making it a complete single-tablet regimen 1, 5
Evidence Supporting BIC/FTC/TAF for PEP
- Clinical studies have demonstrated high completion rates (90-96%) with BIC/FTC/TAF PEP regimens 2
- BIC/FTC/TAF has shown significantly higher completion rates compared to earlier PEP regimens, including Zidovudine/lamivudine plus a protease inhibitor (38.8%) 5, twice daily raltegravir plus TDF/FTC (57.0%) 2, and co-formulated elvitegravir/cobicistat/TDF/FTC (71.0%) 2
Important Clinical Considerations
- The CDC recommends initiating PEP as soon as possible after exposure, preferably within 1-2 hours, but can be started up to 72 hours post-exposure 3
- HIV testing should be performed before initiating PEP and at follow-up intervals (4-6 weeks and 12 weeks after exposure) 3
- PEP can be discontinued if the source is found to be HIV-negative at any point during the course 3
Special Populations
- The CDC recommends BIC/FTC/TAF as a preferred regimen for children aged ≥2 years and weighing ≥14 kg 1, 5
- For pregnant women, the recommended ART regimen is dolutegravir with TAF/FTC, according to Praxis Medical Insights 6
Common Pitfalls to Avoid
- Mistaking PEP for a single-dose intervention, when it requires a full 28-day course, as emphasized by the CDC 1, 2
- Delaying initiation beyond 72 hours post-exposure reduces effectiveness, as noted by Praxis Medical Insights 3
- Failing to check for drug interactions, particularly with medications containing polyvalent cations, is a common pitfall to avoid, according to Praxis Medical Insights 6